Propanc Biopharma has signed a services agreement with Berlin-based FyoniBio to develop and validate an LC-MS pharmacokinetics assay capable of quantifying four analytes — the proenzymes trypsinogen and chymotrypsinogen and their activated enzyme forms — in human serum at a target sensitivity of at least 0.1 µg/mL. The assay will support a planned Phase 1b, first-in-human study of PRP in advanced solid tumors, with trial initiation targeted for the fourth quarter. The bioanalytical work is one of three stated prelaunch workstreams alongside GMP manufacture of PRP and submission of the clinical trial application.
The move addresses a core risk for enzyme-based biologics: reliably distinguishing zymogen and active forms in a complex matrix where endogenous inhibitors and degradation can confound measurement. Sponsors often default to immunoassays at this stage, but LC-MS offers specificity across closely related analytes and is better suited to parsing activation states — a critical requirement if dose selection and exposure–response decisions hinge on seeing both the administered proenzymes and the catalytically active species in circulation. Pairing the assay effort with GMP readiness signals a push to lock CMC and bioanalytical foundations before first patient in, rather than backfilling under pressure later.
Strategically, outsourcing to a specialist CDO reflects a lean development posture and an acknowledgement that bioanalytical credibility will carry disproportionate weight here. With a two-component biologic meant to activate in vivo, regulators will expect clarity on systemic exposure, conversion kinetics, and stability, aligned with the FDA/EMA M10 bioanalytical validation framework. The 0.1 µg/mL lower limit of quantification sets an achievable bar, but sensitivity alone will not de-risk the program; matrix effects, parallelism, analyte stability, and interference from endogenous proteases and inhibitors will all need to be resolved in validation.
For sites, the choice of LC-MS and the need to capture both proenzyme and active forms implies a tightly controlled sampling and processing playbook. Expect standardized blood collection tubes, immediate addition of protease inhibitors, defined centrifugation times, and rapid cold-chain shipment to a central lab. That raises operational load and training requirements, particularly if the trial spans multiple countries. CROs and central labs will need to coordinate sample logistics to prevent ex vivo activation that could skew PK profiles. Clean PK readouts, however, should enable more decisive dose escalation and limit mid-trial protocol amendments, which can be costlier than front-loaded assay development.
Sponsors watching this space will note the broader development questions still pending. PRP’s mechanism — targeting recurrence and metastasis via proenzyme activation — will likely require pharmacodynamic markers beyond exposure to inform go/no-go. Without tumor-type enrichment, a basket-like FIH in heavily pretreated patients risks diluting early efficacy signals; biomarker strategy, immunogenicity assessment, and ADA assay readiness will be pivotal to interpretability. Manufacturing also looms large: co-formulation, lot-to-lot ratio control of the two proenzymes, and comparability planning will be scrutinized alongside bioanalytical data.
Near term, the milestones to watch are completion of method validation with a full report meeting M10 expectations, release of GMP PRP drug product, and confirmation of clinical trial authorization. Assay transfer robustness, preanalytical variance at sites, and demonstration that the active enzymes can be measured reliably in patient serum are material risks. If those pieces come together on schedule, Propanc can enter the clinic with a tighter decision framework than typical for early oncology enzyme programs; if not, assay gaps could become the rate-limiting step for dose selection and signal detection in Phase 1b.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
